Rani Therapeutics Holdings, Inc. (RANI) - Dilution Analysis

Visualizing historical and potential share dilution over time

Dilution Analysis

High Risk
Significant dilution risk
Last updated: March 26, 2026

Risk Assessment Details

Potential Dilution: 312.26% of current shares
Recent Dilution: 163.44% (2 years)
Historical Dilution Factor: significant recent dilution
Outstanding Shares
100M
Potential Supply
310M
Additional shares possible
Splits
None
Past 2 years

Summary

RANI currently has 99.7M outstanding shares. with significant dilution risk as 311M authorized shares could dilute existing holders by 312.3%. The company has significantly diluted shareholders by 163.44% over the past 2 years, indicating aggressive capital raising.

Share Structure Timeline

Outstanding Shares
Total Supply

Historical Data Points

Date Event Outstanding Supply
Mar 26, 2026

10-K filing | 99.7M shares outstanding

100M 310M
Nov 07, 2025

S-3 filing: This prospectus relates to the proposed resale from time to time by the selling stockholders of up to 42,633,337 shares of our Class A common stock; up to 125,000,004 shares of our Class A common stock issuable upon the exercise of outstanding common stock warrants; and up to 82,366,667 shares of our Class A common stock issuable upon the exercise of outstanding pre-funded warrants.

98M 310M
Nov 06, 2025

10-Q filing | 97.5M shares outstanding

98M 61M
Aug 08, 2025

S-3 filing: The filing is an S-3 registration statement for the potential offering of up to $200,000,000 in aggregate amount of Class A common stock, preferred stock, debt securities, or warrants, either individually or in combination.

48M 61M
Aug 07, 2025

10-Q filing | 47.9M shares outstanding

48M 61M
Jul 03, 2025

S-3 filing: This S-3 filing relates to the proposed resale from time to time by the selling stockholder of up to 13,160,172 shares of Class A common stock issuable upon exercise of a Series D common stock warrant.

33M 61M
May 13, 2025

10-Q filing | 33.4M shares outstanding

33M 48M
Mar 31, 2025

10-K filing | 33.5M shares outstanding

34M 48M
Nov 14, 2024

10-Q filing | 33.3M shares outstanding

33M 48M
Aug 06, 2024

10-Q filing | 29.3M shares outstanding

29M 48M
May 06, 2024

10-Q filing | 26.0M shares outstanding

26M 48M
Mar 20, 2024

10-K filing | 26.0M shares outstanding

26M 48M
Nov 08, 2023

10-Q filing | 25.6M shares outstanding

26M 48M
Aug 11, 2023

10-Q filing | 25.3M shares outstanding

25M 48M
May 10, 2023

10-Q filing | 25.2M shares outstanding

25M 48M
Mar 22, 2023

10-K filing | 25.3M shares outstanding

25M 48M
Dec 16, 2022

S-3 filing: This prospectus relates to the resale from time to time of up to 6,009,542 shares of Class A common stock held by selling stockholders. The company will not receive any proceeds from the sale of these shares.

24M 48M
Nov 10, 2022

10-Q filing | 24.5M shares outstanding

24M 42M
Aug 10, 2022

10-Q filing | 24.4M shares outstanding

24M 42M
Aug 01, 2022

S-3 filing: The filing is an S-3 prospectus for a shelf offering of up to $400,000,000 in a combination of securities, including Class A common stock, preferred stock, and debt securities. The specific terms of the offerings will be detailed in prospectus supplements.

24M 42M
May 11, 2022

10-Q filing | 24.5M shares outstanding

24M 6.7M
Mar 31, 2022

10-K filing | 24.4M shares outstanding

24M 6.7M
Nov 16, 2021

10-Q filing | 19.7M shares outstanding

20M 6.7M
Sep 13, 2021

10-Q filing | 29.3M shares outstanding

29M 6.7M
Jul 26, 2021

S-1/A filing: This is an S-1/A filing for the initial public offering of Class A common stock of Rani Therapeutics Holdings, Inc. The company is offering 6,666,667 shares with an estimated price range of $14.00 to $16.00 per share.

N/A 6.7M
Jul 16, 2021

S-1/A filing: This is an S-1/A filing for Rani Therapeutics Holdings, Inc. registering Class A common stock with a proposed maximum aggregate offering price of $100,000,000.

N/A 0
Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam Unsubscribe anytime